4.6 Article

The association between anticoagulation and adverse outcomes after a positive SARS-CoV-2 test among older outpatients: A population-based cohort study

期刊

THROMBOSIS RESEARCH
卷 211, 期 -, 页码 114-122

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.thromres.2021.12.010

关键词

SARS-CoV-2; Coronavirus disease 2019 (COVID-19); Anticoagulants; Mortality; Hospitalization

资金

  1. Sunnybrook Foun-dation [R21HL140381]
  2. National New Investigator Award from the Heart and Stroke Foundation of Canada [IIR-19-134]
  3. Heart and Stroke Foundation of Ontario
  4. VA Geriatric Research Education Clinical Center, Tennessee Valley Healthcare System, National Institutes of Health
  5. VA
  6. Pfizer
  7. Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine
  8. Heart and Stroke Foundation of Nova Scotia Endowed Chair in Cardiovascular Outcomes Research
  9. Jack Tu Chair in Cardiovascular Outcomes Research, Sunnybrook Hospital
  10. Department of Emergency Services at Sunnybrook Health Sciences
  11. Sunnybrook Research Institute

向作者/读者索取更多资源

For outpatients aged > 65 years, oral anticoagulation at the time of a positive SARS-CoV-2 test was associated with a lower risk of a composite of death or hospitalization within 60 days.
Introduction: Anticoagulation may improve outcomes in patients with COVID-19 when started early in the course of illness. Materials and methods: This was a population-based cohort study using linked administrative datasets of outpatients aged > 65 years old testing positive for SARS-CoV-2 between January 1 and December 31, 2020 in Ontario, Canada. The key exposure was anticoagulation with warfarin or direct oral anticoagulants before COVID-19 diagnosis. We calculated propensity scores and used matching weights (MWs) to reduce baseline differences between anticoagulated and non-anticoagulated patients. The primary outcome was a composite of death or hospitalization within 60 days of a positive SARS-CoV-2 test. We used the Kaplan-Meier method and cumulative incidence functions to estimate risk of the primary and component outcomes at 60 days. Results: We studied 23,159 outpatients (mean age 78.5 years; 13,474 [58.2%] female), among whom 3200 (13.8%) deaths and 3183 (13.7%) hospitalizations occurred within 60 days of the SARS-CoV-2 test. After application of MWs, the 60-day risk of death or hospitalization was 29.2% (95% CI 27.4%-31.2%) for anti coagulated individuals and 32.1% (95% CI 30.7%-33.5%) without anticoagulation (absolute risk difference [ARD],-2.9%; p = 0.005). Anticoagulation was also associated with a lower risk of death: 18.6% (95% CI 17.0%-20.2%) with anticoagulation and 20.9% (95% CI 19.7%-22.2%) in non-anticoagulated patients (ARD-2.3%; p = 0.005). Conclusions: Among outpatients aged > 65 years, oral anticoagulation at the time of a positive SARS-CoV-2 test was associated with a lower risk of a composite of death or hospitalization within 60 days.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据